ALXO
ALX ONCOLOGY HOLDINGS INC
NASDAQ · Healthcare · Biotechnology · US
$1.14
+7.55%Oct 15, 2026, 21:07 UTC
ALX ONCOLOGY HOLDINGS INC entered into an exchange agreement under which stockholders surrendered 13,353,384 common shares for no consideration and the company issued pre-funded warrants to purchase 13,353,384 common shares at $0.001 per share.
Sep 28, 2026, 12:00 UTC
ALX Oncology announced the publication in Nature Medicine of ASPEN-06 Phase 2 clinical data showing evorpacept plus trastuzumab, ramucirumab and paclitaxel achieved a 40.3% overall response rate versus 26.6% for control in HER2-positive gastric cancer.
Source:Aug 6, 2026, 12:00 UTC
ALX Oncology announced the appointments of Scott Garland as Chairman of the Board of Directors and Michael Listgarten as General Counsel.
Source:Aug 6, 2026, 00:00 UTC
ALX Oncology Holdings refinanced $10 million of existing debt and obtained an additional $20 million under a new $50 million loan facility, with $10 million uncommitted.
Aug 6, 2026, 00:00 UTC
ALX Oncology Holdings reported a Q2 2026 net loss of $17.97 million, or $0.13 per diluted share, with cash and investments of $153.4 million as of June 30, 2026.
Jun 26, 2026, 00:00 UTC
ALX Oncology Holdings Inc. entered into a secured multi-tranche term loan facility with HSBC Ventures USA Inc., drawing $10 million at closing to refinance existing debt and pay closing costs, with additional tranches available through June 30, 2028, maturing June 1, 2030.